FPT-CORPORATION
1.3.2024 08:37:38 CET | Business Wire | Press release
FPT Corporation (FPT) has acquired the IT services company Next Advanced Communications NAC Co., Ltd. (NAC), making it FPT’s first merger & acquisition (M&A) deal in Japan. With NAC as FPT’s wholly-owned subsidiary, the company aims to double its customer base and service offerings, deepening its foothold in the Japanese market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229752610/en/
The strategic investment signing ceremony between NAC and FPT took place in Tokyo, Japan (Photo: Business Wire)
The strategic move aligns with FPT’s global expansion strategy and enables the Vietnamese firm to capitalize on NAC’s talent pool of nearly 300 experienced engineers and strong expertise centred on technology and business consulting, architecture design, system planning, design, development, and operation. With these additional resources, FPT aims to achieve one billion USD in revenue from the Japanese market by 2027 and have more than half of its employees in Japan as multinational employees.
With current challenges for digital transformation in Japan, including an ageing population, shortage of ICT human resources and complexity of existing systems, the acquisition of NAC reflects FPT’s commitment to accompanying Japanese businesses in digital transformation and green transformation. This also enables FPT to foster sustainable growth and competitiveness and expand its services to new industries and a wider range of customers.
"Like NAC, FPT strives to leverage technology to address a variety of customer issues, with the goal of creating a sustainable society for everyone. We aim to enhance the Japanese engineer talent pool and cooperate with local companies to help our clients maintain business continuity despite geopolitical challenges. Additionally, FPT prioritizes and fosters a multicultural work environment. I believe NAC and FPT employees will find greater success and happiness in our collaboration," said Do Van Khac, FPT Software Senior Executive Vice President and FPT Japan CEO.
Naoto Yamazaki, NAC Chairman, said: “Since we started NAC 13 years ago, we have achieved success as an independent company. Today, as we join the FPT family, I believe not only can we maintain our growth but also form a stronger synergy for the future. NAC and FPT will strive to accelerate our business more than ever and become a company that can contribute to society.”
Since 2014, FPT has completed multiple M&A deals in the US and Europe. In Japan, the firm recently formed a joint venture with Konica Minolta and made a strategic investment in LTS Inc. The acquisition of NAC, as FPT’s first M&A deal in Japan, highlights its focused, long-term commitment to this key market. This also generates momentum for the corporation’s future M&A activities.
FPT has nearly two decades of presence in the Japanese market with the operation of FPT Japan, one of the country’s largest foreign-invested tech firms in terms of human resources. With a workforce of 2,900 onsite employees, nearly 15,000 employees working from overseas, 16 local offices and innovation hubs, FPT Japan has provided services and solutions to over 450 clients worldwide. The company is also recognized for excellent employee benefits and workplace happiness, earning accolades such as Best Workplaces in Asia, Best Places To Work in Japan, and Best Places To Work for Women in Japan.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 70,000+ employees. For more information, please visit https://fpt.com.vn/en.
About NAC Co., Ltd.
NAC Co., Ltd. was established on March 31, 2011. The company's main businesses are marketing, consulting support, system planning, and system design, development, operation, and maintenance. By providing these services, NAC aims to realize a sustainable future as a member of the FPT Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229752610/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom